Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance

Amylx Pharmaceuticals IncTrade
YieldMax AI & Tech Portfolio Option Income ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.57 (market cap $2.64B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.

AMLXGPTY
Market Cap
$2.64B
Sector
HealthIncome / Options Overlay
52-Week High
$24.19$50.52
52-Week Low
$7.82$34.73
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

YieldMax AI & Tech Portfolio Option Income ETF

GPTY trades at $43.11, up 1.07% with a bullish technical signal supported by moving averages. The YieldMax AI & Tech Portfolio Option Income ETF demonstrates consistent weekly dividend distributions, with recent payouts ranging from $0.28-$0.37. Technical indicators show strong momentum with RSI at 83.06 suggesting potential overbought conditions, while support and resistance cluster around $42-$43 levels.

The ETF's strategy of harvesting options premiums from AI and semiconductor stocks provides high yield exposure, though the concentrated tech focus and elevated RSI levels warrant caution. Recent analysis highlights GPTY's balance of income generation and capital preservation compared to peers, but dependence on semiconductor momentum presents volatility risks.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About YieldMax AI & Tech Portfolio Option Income ETF

GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.

Read more on GPTY